View details of this raise on Seedstage

Boston, MA

Scaling an AI-powered platform that helps health plans identify and treat high-need patients with precision care.

• Faster diagnosis: Reduces seven-year rare disease journeys to twelve weeks using AI.
• Validated partnerships: Active engagements with health plans covering over 8.5 million lives.
• High patient opt-in: 90% of patients offered services choose to participate.
• Scalable platform: Flat-fee, software-first model designed to grow across multiple diseases.
• Strong leadership: Founded by seasoned healthcare and tech experts with deep industry ties.

TMA Precision Health is raising capital to scale its AI-powered platform that helps health plans proactively identify high-cost, high-need patients—especially those with rare or genetic conditions—and deliver faster, more effective care. Their technology shortens the typical seven-year diagnostic journey into just 12 weeks, enabling earlier diagnosis, improved outcomes, and significant cost savings. TMA’s model is built around partnerships with health plans, not patients, ensuring services are fully covered and removing barriers for families seeking answers. The company’s initial focus is pediatric epilepsy, with plans to expand across multiple complex disease categories.

With proven results from hundreds of cases and growing traction with U.S. health plans, TMA is positioned to scale to 1,000 patients per month and expand its reach to over a million covered lives. The company combines deep clinical expertise, proprietary data models, and AI to deliver precision care solutions at speed and scale. Funding from this round will enable expansion into a second disease vertical and further development of their end-to-end infrastructure. Backed by experienced founders, prominent advisors, and leading venture firms, TMA aims to become the go-to partner for precision care in the U.S. healthcare system.

Company Info

TMA Precision Health uses AI to help health plans identify high-cost patients early and deliver personalized treatment insights to reduce costs and improve outcomes.

TMA Precision Health provides an AI-enabled precision medicine platform designed to help health plans identify and manage high-cost, complex patients more effectively. The company works directly with insurers to analyze claims data, flag hidden patients—especially those with rare or genetic diseases—and deliver tailored treatment insights within 12 weeks, compared to the typical multi-year diagnostic process. TMA’s solution is HIPAA-compliant and structured to integrate seamlessly with existing health plan systems, using a flat-fee, pay-for-results model that eliminates cost or complexity for families.

Initially focused on pediatric epilepsy, TMA is expanding its platform to other complex disease categories such as autism, cardiometabolic, and neuromuscular conditions. With early traction across U.S. health plans covering millions of lives, the company is scaling toward serving over 1,000 patients per month. TMA has built one of the largest proprietary datasets linking genomic and real-world clinical data, strengthening its AI models and enabling future capabilities in drug matching, clinical trial optimization, and personalized insurance products. Led by a team with expertise in genomics, AI, and healthcare operations, TMA is positioning itself as an end-to-end solution for precision medicine at scale.